outbreak
novel
coronaviru
diseas
caus
new
coronaviru
offici
design
sever
acut
respiratori
syndromerel
coronaviru
repres
pandem
threat
global
public
health
although
epicent
outbreak
decemb
locat
wuhan
china
diseas
spread
countri
figur
confirm
case
confirm
death
worldwid
figur
march
addit
million
peopl
live
affect
result
mandatori
isol
quarantin
rippl
effect
outbreak
could
potenti
bring
major
challeng
worldwid
health
system
farreach
consequ
global
economi
spread
viru
effect
control
coronavirus
cov
rel
larg
virus
contain
singlestrand
positivesens
rna
genom
encapsul
within
membran
envelop
viral
membran
stud
glycoprotein
spike
give
coronavirus
crownlik
appear
figur
coronavirus
infect
human
anim
certain
type
anim
bat
host
largest
varieti
coronavirus
appear
immun
coronavirusinduc
ill
four
class
coronavirus
design
alpha
beta
gamma
delta
betacoronaviru
class
includ
sever
acut
respiratori
syndrom
sar
viru
sarscov
middl
east
respiratori
syndrom
mer
viru
merscov
caus
agent
similar
sarscov
merscov
attack
lower
respiratori
system
caus
viral
pneumonia
may
also
affect
gastrointestin
system
heart
kidney
liver
central
nervou
system
lead
multipl
organ
failur
current
inform
indic
transmissiblecontagi
sarscov
sinc
outbreak
novel
coronaviru
diseas
caus
viru
diseas
spread
rapidli
around
globe
consid
potenti
threat
pandem
scientist
physician
race
understand
new
viru
pathophysiolog
diseas
uncov
possibl
treatment
regimen
discov
effect
therapeut
agent
vaccin
support
current
research
develop
ca
produc
special
report
provid
overview
publish
scientif
inform
emphasi
patent
ca
content
collect
highlight
antivir
strategi
involv
small
molecul
biolog
target
complex
molecular
interact
involv
coronaviru
infect
replic
drugrepurpos
effort
document
herein
focus
primarili
agent
known
effect
rna
virus
includ
sarscov
merscov
patent
analysi
coronavirusrel
biolog
includ
therapeut
antibodi
cytokin
nucleic
acidbas
therapi
target
viru
gene
express
well
variou
type
vaccin
patent
disclos
methodolog
four
biolog
potenti
treat
prevent
coronaviru
infect
may
applic
inform
includ
report
provid
strong
intellectu
groundwork
ongo
develop
therapeut
agent
vaccin
betacoronaviru
genom
encod
sever
structur
protein
includ
glycosyl
spike
protein
function
major
induc
host
immun
respons
protein
mediat
host
cell
invas
sarscov
via
bind
receptor
protein
call
angiotensinconvert
enzym
locat
surfac
membran
host
cell
recent
studi
also
reveal
invas
process
requir
protein
prime
facilit
host
cellproduc
serin
proteas
addit
viral
genom
also
encod
sever
nonstructur
protein
includ
rnadepend
rna
polymeras
rdrp
coronaviru
main
proteas
papainlik
proteas
plpro
upon
entranc
host
cell
viral
genom
releas
singlestrand
posit
rna
subsequ
translat
viral
polyprotein
use
host
cell
protein
translat
machineri
cleav
effector
protein
viral
proteinas
plpro
plpro
also
behav
deubiquitinas
may
deubiquin
certain
host
cell
protein
includ
interferon
factor
result
immun
suppress
rdrp
synthes
fulllength
negativestrand
rna
templat
use
rdrp
make
viral
genom
rna
interact
viral
protein
host
cell
surfac
signific
interest
sinc
initi
infect
process
cryoem
structur
analysi
reveal
bind
affin
protein
time
higher
sarscov
protein
specul
may
contribut
report
higher
transmiss
contagi
compar
sarscov
prospect
also
exist
discoveri
therapeut
agent
target
highli
conserv
protein
associ
sarscov
rdrp
proteas
share
sequenc
similar
sarscov
despit
fact
two
virus
demonstr
sequenc
similar
genom
level
basi
sequenc
align
homolog
model
sarscov
share
highli
conserv
receptorbind
domain
rbd
domain
protein
sequenc
similar
protein
addit
although
plpro
sequenc
sarscov
similar
share
similar
activ
site
date
antivir
agent
research
race
find
possibl
treatment
save
live
produc
vaccin
futur
prevent
support
research
develop
effort
discov
effect
therapeut
prevent
agent
ca
divis
american
chemic
societi
special
scientif
inform
solut
analyz
scientif
data
relat
develop
therapeut
agent
vaccin
human
coronavirus
sinc
analys
present
report
base
ca
content
collect
scientistcur
data
collect
cover
publish
scientif
literatur
patent
patent
author
worldwid
subset
analys
ca
medlin
data
collect
analyz
sar
mer
trend
scientif
public
relat
sinc
outbreak
new
diseas
caus
viru
drawn
major
global
attent
scientist
physician
worldwid
conduct
major
campaign
understand
new
emerg
diseas
epidemiolog
effort
uncov
possibl
treatment
regimen
discov
effect
therapeut
agent
develop
vaccin
figur
show
total
number
journal
articl
relat
publish
week
last
week
week
februari
journal
articl
publish
electron
print
period
number
publish
articl
increas
week
sinc
week
januari
although
larg
portion
articl
clinic
manifest
treatment
option
increas
number
studi
focus
elucid
viru
structur
viru
transmiss
mechanismsdynam
well
identif
antivir
agent
accur
diagnost
viru
detect
trend
reflect
immens
interest
desir
scientif
commun
includ
academ
industri
organ
well
clinician
identifi
new
method
halt
progress
epidem
diseas
prevent
infect
transmiss
futur
notabl
journal
articl
relat
tabl
list
journal
articl
publish
decemb
februari
articl
select
base
collect
use
factor
journal
impact
factor
citat
type
studi
exampl
articl
list
character
genom
greatli
facilit
global
effort
develop
vaccin
prevent
also
shown
tabl
journal
articl
pertain
potenti
antivir
drug
candid
remdesivir
baricitinib
chloroquin
treatment
diseas
mention
earlier
caus
new
type
coronaviru
genu
sarscov
merscov
viral
protein
respons
entri
host
cell
replic
structur
similar
associ
sarscov
thu
research
develop
sar
mer
may
offer
insight
would
benefici
develop
therapeut
prevent
agent
report
identifi
pertin
data
patent
relat
two
coronavirus
figur
show
distribut
patent
ca
content
collect
relat
sar
mer
b
number
patent
relat
sar
almost
time
number
relat
mer
probabl
sar
outbreak
occur
year
mer
outbreak
among
sar
patent
relat
develop
therapeut
relat
vaccin
relat
diagnost
agent
method
individu
patent
may
cover
two
area
sum
percentag
valu
greater
similar
distribut
pattern
also
observ
patent
relat
mer
thu
diseas
patent
devot
develop
therapeut
agent
oppos
diagnost
method
vaccin
identif
target
import
identifi
drug
high
target
specif
andor
uncov
exist
drug
could
repurpos
treat
infect
tabl
list
potenti
target
role
viral
infect
repres
exist
drug
drug
candid
reportedli
act
correspond
target
similar
virus
thu
assess
effect
infect
plpro
two
viral
proteas
respons
cleavag
viral
peptid
function
unit
viru
replic
packag
within
host
cell
thu
drug
target
proteas
virus
hiv
drug
lopinavir
ritonavir
explor
rdrp
rna
polymeras
respons
viral
rna
synthesi
may
block
exist
antivir
drug
drug
candid
remdesivir
conceiv
interact
viral
protein
receptor
host
cell
subsequ
viral
endocytosi
cell
may
also
viabl
drug
target
exampl
broadspectrum
antivir
drug
arbidol
function
virushost
cell
fusion
inhibitor
prevent
viral
entri
host
cell
influenza
viru
enter
clinic
trial
treatment
proteas
produc
host
cell
play
import
role
proteolyt
process
protein
prime
receptor
bind
human
cell
shown
camostat
mesyl
clinic
approv
inhibitor
abl
block
entri
human
cell
indic
potenti
drug
involv
coronaviru
infect
interest
sinc
potent
neg
regul
restrain
overactiv
reninangiotensin
system
ra
may
involv
elicit
inflammatori
lung
diseas
addit
wellknown
role
regul
blood
pressur
balanc
bodi
fluid
electrolyt
catalyz
degrad
angiotensin
ii
angiotensin
balanc
angiotensin
ii
angiotensin
critic
sinc
angiotensin
ii
bind
angiotensin
receptor
caus
vasoconstrict
wherea
angiotensin
elicit
vasodil
mediat
although
notion
mediat
coronaviru
invas
larg
accept
remain
unclear
level
activ
receptor
receptor
alter
coronavirusinduc
diseas
due
limit
number
studi
therefor
yet
determin
whether
drug
compound
target
protein
eg
partial
antagonist
receptor
partial
agonist
receptor
may
allevi
coronavirusinduc
lung
injuri
patent
potenti
drug
candid
relat
key
protein
target
ca
content
collect
contain
patent
relat
coronaviru
key
protein
list
tabl
list
number
patent
relat
protein
target
associ
therapeut
compound
ca
registri
number
ca
rn
report
patent
ca
data
show
target
rdrp
attract
attent
target
compound
therapeut
potenti
identifi
target
probabl
due
work
done
sarscov
also
contain
rdrp
exist
drug
potenti
therapeut
applic
sinc
newli
discov
pathogen
specif
drug
identifi
current
avail
econom
effici
therapeut
strategi
repurpos
exist
drug
basi
genom
sequenc
inform
coupl
protein
structur
model
scientif
commun
abl
rapidli
respond
suggest
list
exist
drug
therapeut
potenti
tabl
provid
summari
drug
togeth
potenti
mechan
action
activ
barcitinib
propos
antiinflammatori
effect
possibl
abil
reduc
viral
entri
fix
dose
antihiv
combin
current
clinic
trial
arbidol
ribavirin
remdesivir
develop
gilead
scienc
inc
previous
test
human
ebola
viru
diseas
shown
promis
anim
model
mer
sar
drug
current
studi
phase
iii
clinic
trial
china
usa
favipiravir
journal
articl
publish
first
two
month
number
publish
articl
increas
week
sinc
week
januari
purin
nucleosid
lead
inaccur
viral
rna
synthesi
origin
develop
toyama
chemic
japan
recent
approv
clinic
trial
drug
treat
chloroquin
antimalari
drug
proven
effect
treat
coronaviru
china
addit
abovement
mani
antivir
drug
also
list
select
patent
relat
promis
small
molecul
drug
candid
tabl
show
select
patent
associ
aforement
potenti
drug
togeth
patent
disclos
small
molecul
treatment
sar
mer
select
base
presenc
import
term
casindex
patent
well
presenc
synthet
prepar
role
assign
ca
scientist
document
index
patent
applic
disclos
prepar
compound
activ
jak
inhibitor
one
later
name
baricitinib
develop
reduc
inflamm
rheumatoid
arthriti
patent
applic
disclos
prepar
polycycl
pyridon
compound
use
endonucleas
inhibitor
patent
applic
patent
applic
disclos
structur
synthes
compound
variou
structur
class
peptidyl
aldehyd
peptidyl
peptidyl
bisulfit
salt
peptidyl
heterocycl
well
certain
formul
composit
develop
inhibit
viral
proteas
proteas
ie
patent
applic
present
prepar
method
biolog
assay
result
compound
capabl
inhibit
sar
viru
proteas
compound
appear
exhibit
good
enzymeinhibit
activ
pic
ritonavir
pharmacokinet
profil
enhanc
may
potenti
effect
proteas
inhibitor
due
abil
attenu
degrad
drug
liver
enzym
thu
use
combin
antiviri
lopinavir
inhibitor
viral
entri
host
cell
direct
action
protein
yet
confirm
tabl
drug
candid
mostli
inhibit
viral
enzym
includ
proteas
compon
rdrp
sinc
proteas
high
level
sequenc
homolog
sarscov
inhibitor
sarscov
may
also
applic
compound
includ
benzopurpurin
b
may
inhibit
activ
viral
poli
u
specif
endoribonucleas
test
reduc
sarscov
infect
cultur
cell
ic
compound
two
agonist
wherea
dual
function
partial
agonist
receptor
partial
antagonist
receptor
sinc
import
effector
ra
system
belong
specul
compound
may
use
adjust
balanc
may
affect
coronaviru
infect
allevi
viralinduc
lung
injuri
infect
small
molecul
identifi
structur
similar
lipinski
rule
casindex
pharmacolog
activ
andor
therapeut
usag
besid
aforement
antivir
drug
may
addit
small
molecul
compound
therapeut
pharmacolog
potenti
virus
sarscov
merscov
compound
list
tabl
subject
tanimoto
similar
search
ca
registri
use
ca
proprietari
fingerprint
substanc
least
structur
similar
match
meet
lipinski
rule
identifi
tabl
list
select
compound
also
identifi
pharmacolog
activ
therapeut
usag
role
compound
name
ca
rn
provid
compound
second
column
list
number
compound
met
structur
similar
lipinski
rule
criteria
although
work
remain
done
regard
methodolog
result
mention
point
strategi
may
help
streamlin
process
drug
discoveri
biolog
coronavirusassoci
diseas
distribut
biolog
patent
relat
sar
mer
new
coronaviru
relat
sar
mer
virus
caus
seriou
ongo
epidemiolog
problem
around
world
sinc
limit
clinic
basic
research
inform
time
treatment
option
current
compris
investig
drug
manag
symptom
biolog
potenti
broaden
spectrum
treatment
option
coronavirusinduc
diseas
leverag
prior
knowledg
practic
use
address
sar
mer
outbreak
provid
practic
strategi
develop
new
targetspecif
therapeut
agent
end
analysi
biolog
patent
contain
ca
content
collect
perform
patent
analysi
includ
inform
relat
therapeut
antibodi
cytokin
interf
therapeut
rna
vaccin
potenti
treatment
andor
prevent
sarsrel
diseas
patent
publish
present
figur
show
patent
disclos
use
four
biolog
class
treat
prevent
sar
mer
patent
vaccin
develop
largest
class
follow
therapeut
antibodi
interf
rna
cytokin
given
indispens
role
vaccin
viral
diseas
prevent
detail
analysi
vaccin
present
later
section
antibodi
ninetynin
patent
contain
inform
antibodi
therapeut
andor
diagnost
potenti
sar
mer
identifi
patent
claim
prepar
sarsspecif
antibodi
mersspecif
antibodi
antibodi
diagnost
applic
similar
sarscov
receptorbind
domain
rbd
protein
bind
human
receptor
order
gain
access
host
cell
viral
infect
protein
structur
protein
e
n
sarscov
elicit
immun
respons
tabl
show
target
analysi
patent
relat
develop
therapeut
antibodi
sar
antibodi
direct
protein
includ
rbd
data
indic
protein
put
target
antibodi
develop
addit
patent
contain
inform
pertain
type
antivir
antibodi
use
sar
mer
therapi
includ
neutral
antibodi
antibodi
design
target
protein
tolllik
receptor
itam
immunoreceptor
tyrosinebas
activ
motif
dcsign
dendrit
cellspecif
intercellular
adhes
moleculegrab
nonintegrin
intercellular
adhes
molecul
interferon
protein
cytokin
storm
report
correl
diseas
sever
infect
patient
admit
icu
higher
concentr
proinflammatori
cytokin
chemokin
particularli
gcsf
monocyt
chemoattract
protein
well
elev
cytokin
helper
cell
patent
applic
besid
variou
commerci
antivir
drug
also
small
molecul
compound
current
r
shown
signific
inhibitori
effect
mani
key
protein
virus
patent
disclos
use
four
biolog
class
therapeut
antibodi
cytokin
rna
therapi
vaccin
treat
prevent
sar
mer
analyz
studi
disclos
human
antibodi
includ
bispecif
molecul
immunoconjug
bind
high
affin
treat
inflamm
autoimmun
diseas
neurodegen
diseas
bacteri
infect
viral
infect
patent
applic
disclos
prepar
human
antibodi
immunoconjug
specif
target
chemokin
includ
antibodi
shown
suppress
free
serum
day
mgkg
approxim
day
mgkg
cynomolgu
macaqu
addit
type
ii
transmembran
adhes
molecul
ctype
lectin
function
mainli
express
interstiti
dendrit
cell
lung
alveolar
macrophag
dcsign
function
entri
cofactor
transfer
sarscov
suscept
cell
pneumocyt
patent
applic
claim
product
human
antidcsign
antibodi
interf
interact
dcsign
receptor
antibodi
effect
block
viral
bind
infect
transmiss
viral
infectionsdiseas
includ
sar
cytokin
cytokin
lowmolecularweight
protein
act
chemic
signal
immun
respons
pathogen
invas
product
variou
cytokin
respons
invad
pathogen
viru
contribut
host
organ
abil
elimin
pathogen
specif
type
cytokin
includ
chemokin
interferon
ifn
interleukin
lymphokin
report
character
literatur
past
year
earli
ca
lexicon
contain
term
specif
type
cytokin
associ
document
includ
patent
viral
infect
promin
cytokin
produc
ifn
interfer
viral
replic
ifn
classifi
type
type
ii
type
iii
base
receptor
complex
use
signal
well
sequenc
homolog
abil
interfer
viral
replic
interferon
interferon
fusion
protein
util
therapeut
agent
treatment
viral
infect
past
year
patent
disclos
protein
use
treat
sar
describ
rsifnco
patent
applic
describ
clone
recombin
interferon
rsifnco
ca
rn
well
method
determin
potenc
effect
treat
variou
viral
infectionsdiseas
includ
sar
invent
relat
rsifnco
ident
amino
acid
sequenc
infergen
alter
spatial
conform
differ
biolog
potenc
rsifnco
antivir
activ
time
stronger
clinic
avail
interferon
also
significantli
stronger
antitumor
properti
breast
cancer
cervic
cancer
recombin
human
invent
relat
rsifn
reduc
toxic
side
effect
safe
use
larg
dose
dose
million
iu
make
possibl
success
treat
viral
diseas
tumor
requir
larg
dose
interferon
patent
applic
disclos
amino
acid
sequenc
recombin
human
interferon
rn
shown
antisar
viral
activ
similar
effect
decreas
diseas
sever
inhibit
prolifer
coronaviru
strain
monkey
variant
patent
applic
claim
method
treat
sar
viral
infect
use
cystein
variant
conjug
polym
eg
polyethylen
glycol
disclos
amino
acid
nucleic
acid
sequenc
cystein
variant
variant
rn
specif
shown
inhibit
viral
replic
interferonhuman
serum
albumin
fusion
protein
patent
applic
disclos
longlast
fusion
protein
hsaifn
compos
interferon
fuse
human
serum
albuminbind
peptid
treatment
wide
rang
diseas
includ
sar
specif
hsaifn
fusion
protein
construct
use
five
differ
interferon
correspond
ca
rn
respect
hsaifn
fusion
protein
significantli
lengthen
plasma
halflif
interferon
eg
h
day
due
slower
free
interferon
releas
plasma
thu
may
prolong
effect
interferon
inject
rna
therapi
rna
interfer
rnai
biolog
process
wherein
small
complementari
rna
duplex
target
neutral
specif
mrna
molecul
result
inhibit
gene
express
genet
translat
interf
rna
includ
microrna
small
interf
rna
sirna
gener
nucleotid
length
short
hairpin
rna
shrna
artifici
synthet
rna
molecul
design
fold
tight
hairpin
conform
allow
silenc
target
gene
serv
precursor
sirna
express
shrna
cell
typic
accomplish
deliveri
via
plasmid
viral
bacteri
vector
although
microrna
noncod
natur
found
plant
anim
virus
synthet
version
current
use
silenc
varieti
gene
abil
chemic
synthes
modifi
analogu
microrna
well
sirna
capabl
alter
diseaserel
gene
express
inhibit
pathogen
gene
express
creat
host
new
therapeut
option
contrast
microrna
sirna
antisens
rna
singlestrand
rna
natur
occur
synthet
usual
around
nucleotid
length
sequenc
complementari
protein
code
mrna
allow
hybrid
block
protein
translat
sinc
discoveri
rnai
late
becom
wellknown
method
silencingsuppress
target
gene
associ
virul
pathogenesi
thirtyf
patent
ca
content
collect
disclos
use
rnai
treat
sar
patent
use
sirna
molecul
three
patent
use
antisens
oligonucleotid
two
patent
use
rna
aptam
one
patent
use
ribozym
one
patent
use
microrna
inhibitor
support
inform
tabl
provid
highlevel
view
patent
includ
specif
rnai
target
patent
discuss
sirna
target
coronaviru
protein
n
e
patent
applic
disclos
two
doublestrand
rna
dsrna
design
specif
target
two
separ
region
sar
protein
mrna
sequenc
target
region
protein
mrna
correspond
ca
rn
sequenc
target
region
correspond
ca
rn
interfer
effici
two
sirna
sar
protein
gene
express
greater
patent
applic
disclos
sequenc
associ
sirna
specif
design
target
n
e
gene
sar
three
sirna
no
shown
inhibit
express
gfpm
gfpn
gfpe
fusion
protein
respect
addit
three
sirna
no
prepar
contain
mutat
end
bold
letter
sens
strand
modifi
sirna
shown
demonstr
increas
inhibit
sar
viru
gene
express
compar
origin
sirna
sirna
target
replicas
rna
polymeras
region
patent
applic
disclos
six
sirna
target
replicas
region
sar
shown
inhibit
viru
infect
replic
effici
sens
strand
sequenc
correspond
ca
rn
shown
tabl
invent
also
disclos
target
e
n
gene
author
demonstr
inhibit
coronaviru
infect
replic
cell
effect
nearli
complet
inhibit
follow
patent
applic
disclos
sirna
shown
tabl
target
sar
gene
encod
rnadepend
rna
polymeras
helicas
nucleoprotein
n
proteolyt
enzym
sirna
abl
inhibit
kill
sar
viru
strain
proteolyt
enzymetarget
sirna
effect
rna
aptam
two
korean
patent
describ
use
rna
aptam
inhibit
sar
virus
patent
applic
identifi
rna
aptam
antisar
agent
capabl
bind
inhibit
doublestrand
dna
unwind
sar
viru
helicas
relat
patent
applic
kr
describ
rna
aptam
distinct
affin
nucleocapsid
sarscov
potenti
pharmaceut
use
ribozym
patent
applic
describ
therapeut
rnadna
chimer
ribozym
design
recogn
cleav
conserv
common
region
region
loop
structur
gene
coronavirus
includ
sar
ribozym
specif
recogn
guc
viral
gene
loop
conform
antisens
oligonucleotid
antisens
oligonucleotid
also
develop
reduc
sever
sar
viru
infect
prevent
treat
sar
virusassoci
diseas
detect
viru
human
sampl
diagnos
sar
virusassoci
diseas
patent
applic
publish
ioni
pharmaceut
describ
hybrid
dna
rna
antisens
oligonucleotid
design
disrupt
pseudoknot
frameshift
site
sar
coronaviru
rna
addit
directli
target
viru
antisens
oligonucleotid
may
use
target
diseaserel
protein
involv
inflammatori
process
crucial
develop
safe
effect
vaccin
control
pandem
elimin
spread
ultim
prevent
futur
recurr
sinc
viru
share
signific
sequenc
homolog
two
lethal
coronavirus
sar
mer
vaccin
identifi
patent
relat
sar
mer
virus
could
potenti
facilit
design
vaccin
distribut
patent
relat
sar
mer
among
vaccin
type
antivir
vaccin
gener
fall
one
follow
type
inact
liveattenu
virus
viruslik
particl
vlp
viral
vector
proteinbas
dnabas
mrnabas
vaccin
patent
ca
content
collect
relat
vaccin
develop
prevent
viral
disordersdiseas
includ
sar
mer
patent
disclos
vaccin
noncoronavirus
may
relev
sar
mer
patent
directli
associ
antisar
antim
vaccin
demonstr
immun
respons
support
inform
tabl
contain
addit
inform
sar
mer
vaccinerel
patent
figur
reveal
distribut
patent
among
vaccin
type
relat
sar
mer
seen
patent
disclos
inform
inact
liveattenu
viru
vaccin
patent
describ
dna
vaccin
patent
disclos
inform
viral
vector
vaccin
patent
disclos
inform
vlp
vaccin
three
patent
focus
mrna
vaccin
report
viral
protein
subunit
vaccin
produc
higher
neutral
antibodi
titer
complet
protect
liveattenu
sarscov
fulllength
protein
dnabas
protein
vaccin
unsurprisingli
half
patent
focus
protein
vaccin
compris
protein
subunit
vaccin
vaccin
specif
target
receptor
bind
domain
rbd
subunit
viral
protein
collect
proteingen
prefer
target
total
patent
directli
associ
antisar
antim
vaccin
demonstr
immun
respons
support
inform
tabl
contain
addit
inform
sarsmer
vaccinerel
patent
dnabas
vaccin
patent
applic
disclos
composit
method
inducingenhanc
immun
respons
particularli
antigenspecif
cellmedi
respons
antigen
sar
coronaviru
enhanc
immun
respons
involv
particularli
cytotox
cell
immun
respons
induc
vivo
chimer
nucleic
acid
encod
endoplasm
reticulum
chaperon
polypeptid
eg
calreticulin
link
least
one
antigen
polypeptid
peptid
sarscov
use
gene
gun
deliveri
dnacoat
gold
particl
vaccin
mice
fusion
protein
result
potent
nucleocapsidspecif
humor
cellmedi
immun
respons
vaccin
anim
capabl
significantli
reduc
titer
challeng
vaccinia
vector
express
n
protein
sar
viru
patent
applic
disclos
immunogen
compris
consensu
protein
deriv
merscov
spike
protein
use
dnabas
vaccin
target
merscov
consensu
spike
protein
significantli
induc
humor
cellular
immun
respons
includ
increas
titer
igg
neutral
antibodi
induc
cellular
immun
respons
involv
increas
cell
respons
produc
march
inovio
pharmaceut
inc
announc
design
dna
vaccin
call
plan
human
trial
unit
state
april
proteinbas
vaccin
patent
applic
glaxosmithklin
gsk
disclos
vaccin
capabl
provok
protect
immun
respons
sar
vaccin
compris
protein
immunogen
oilinwat
emuls
adjuv
engin
ectodomain
immunogen
solubl
protein
combin
emuls
adjuv
induc
high
level
antisarscov
antibodi
respons
neutral
antibodi
respons
anim
model
late
februari
gsk
announc
collabor
chines
firm
clover
biopharmaceut
assess
coronaviru
vaccin
candid
collabor
involv
use
clover
proteinbas
coronaviru
vaccin
candid
strimer
gsk
adjuv
system
appli
trimertag
technolog
clover
manufactur
strimer
subunit
vaccin
use
rapid
mammalian
cell
culturebas
express
system
trimertag
advanc
drug
develop
platform
enabl
product
novel
coval
trimer
fusion
protein
better
target
previou
undrugg
pathway
patent
applic
disclos
immunogen
composit
vaccin
associ
protein
sar
coronaviru
trispik
sar
coronaviru
vaccin
prepar
recombin
fulllength
trimer
protein
recombin
protein
shown
exhibit
nativ
antigen
shown
reactiv
convalesc
sar
patient
sera
exhibit
specif
bind
solubl
receptor
promot
antibodydepend
viral
entri
otherwis
refractori
human
raji
b
cell
elicit
protect
challeng
infect
anim
model
patent
applic
antigen
express
inc
subsidiari
generex
disclos
prepar
hybrid
peptid
compos
three
element
includ
invari
chain
ii
key
peptid
antigen
present
enhanc
activ
b
chemic
structur
link
ii
antigen
epitop
c
antigen
epitop
bind
mhc
class
ii
molecul
methodolog
use
creat
iikey
mhc
ii
sar
hybrid
recent
generex
announc
develop
vaccin
follow
contractu
agreement
chines
consortium
compris
china
technolog
exchang
beij
zhonghua
invest
fund
manag
biolog
institut
shandong
academi
scienc
sinotekadvoc
intern
industri
develop
compani
util
iikey
immun
system
activ
technolog
produc
viral
peptid
human
clinic
trial
viruslik
particl
vaccin
patent
applic
novavax
disclos
immunogen
composit
compos
merscov
nanoparticl
vlp
contain
least
one
trimer
protein
produc
baculoviru
overexpress
cell
vlp
prepar
induc
neutral
antibodi
respons
mice
transgen
cattl
administ
along
proprietari
adjuv
matrix
rn
addit
prepar
sera
vaccin
cattl
inject
transduc
balbc
mice
prior
challeng
merscov
abl
protect
mice
merscov
infect
singl
prophylact
inject
novavax
announc
februari
begin
anim
test
potenti
vaccin
candid
due
previou
experi
work
coronavirus
includ
mer
sar
candid
vaccin
target
protein
develop
use
recombin
nanoparticl
vaccin
technolog
along
proprietari
adjuv
matrixm
mrnabas
vaccin
potenti
advantag
mrna
approach
prophylact
vaccin
includ
abil
mimic
natur
infect
stimul
potent
immun
respons
well
abil
combin
multipl
mrna
singl
vaccin
patent
applic
moderna
disclos
mrna
vaccin
compos
mrna
encod
antigen
viral
fulllength
protein
sarscov
merscov
viru
formul
cation
lipid
nanoparticl
show
mice
vaccin
mrna
encod
coronaviru
fulllength
protein
gener
much
higher
neutral
antibodi
titer
compar
mrna
encod
protein
subunit
new
zealand
white
rabbit
immun
merscov
mrna
vaccin
encod
fulllength
protein
reduc
viral
load
lung
rabbit
induc
signific
amount
neutral
antibodi
merscov
moderna
announc
februari
releas
first
batch
use
human
prepar
use
method
strategi
outlin
previou
patent
vial
ship
nation
institut
allergi
infecti
diseas
niaid
divis
nation
institut
health
nih
use
plan
phase
studi
unit
state
moderna
report
mrna
vaccin
target
prefusionstabil
form
protein
associ
select
moderna
collabor
investig
niaid
vaccin
research
center
manufactur
batch
fund
coalit
epidem
prepared
innov
patent
applic
describ
vaccin
compris
mrna
encod
least
one
antigen
mer
coronaviru
prefer
protein
protein
fragment
envelop
protein
e
membran
protein
nucleocapsid
protein
n
effect
induc
antigenspecif
immun
respons
intraderm
administr
mice
lipid
nanoparticl
lnp
encapsul
mrna
mixtur
encod
merscov
protein
shown
result
translat
vivo
induct
humor
immun
respons
report
provid
overview
publish
inform
global
research
develop
coronavirusrel
therapeut
agent
prevent
vaccin
base
extens
ca
content
collect
focu
patent
includ
overview
coronaviru
morpholog
biolog
pathogenesi
particular
focu
antivir
strategi
involv
small
molecul
drug
well
biolog
target
complex
molecular
interact
involv
coronaviru
infect
replic
drugrepurpos
effort
summar
report
focus
primarili
agent
current
known
effect
rna
virus
includ
sarscov
merscov
influenza
hcv
ebola
well
antiinflammatori
drug
potenti
impact
biolog
treatment
coronaviru
infect
promis
includ
wide
varieti
option
includ
bioengin
vector
antibodi
cytokin
nucleic
acidbas
therapi
target
viru
gene
express
well
variou
type
vaccin
inform
provid
report
provid
strong
intellectu
groundwork
support
ongo
research
develop
discoveri
develop
therapeut
agent
vaccin
treatment
coronavirusrel
diseas
limit
space
report
devot
minim
attent
current
effort
involv
advanc
effici
accur
diagnosi
method
product
novel
infecti
diseas
result
rna
virus
subject
mutat
genet
recombin
well
crossspeci
transmiss
continu
present
seriou
global
health
threat
exemplifi
despit
two
former
major
outbreak
coronaviru
infect
caus
sar
mer
respiratori
ill
world
remain
underprepar
effect
manag
current
outbreak
evidenc
fact
result
thousand
death
worldwid
concert
effort
develop
effect
drug
vaccin
exist
potenti
futur
coronaviru
infect
highli
pathogen
viru
outbreak
necessari
reduc
overwhelm
impact
human
life
worldwid
healthcar
system
given
costli
arduou
process
involv
clinic
drug
develop
outbreak
highlight
valu
develop
rel
broadspectrum
antivir
drug
import
appli
innov
approach
artifici
intellig
facilit
drug
discoveri
given
lengthi
process
new
drug
develop
current
strategi
drug
repurpos
becom
one
chosen
solut
immedi
treatment
infect
individu
longterm
drug
develop
goal
pharmaceut
industri
includ
identif
inhibitor
aim
replic
infect
process
associ
relat
coronavirus
well
symptomat
result
infect
lead
sever
diseas
andor
death
summar
list
contain
report
small
molecul
compound
addit
descript
biolog
properti
suitabl
inhibit
sever
key
coronaviru
protein
could
serv
inform
start
point
drug
develop
sinc
vaccin
crucial
prevent
coronavirusrel
epidem
diseas
futur
reassur
number
innov
strategi
alreadi
deploy
four
mer
coronaviru
dna
vaccin
candid
began
phase
clinic
trial
septemb
moderna
inc
releas
first
batch
februari
mrna
vaccin
readi
phase
studi
unit
state
addit
collabor
area
antivir
discoveri
process
clinic
trial
perform
enhanc
patient
access
drug
candid
improv
therapeut
potenti
ideal
reduc
amount
time
requir
bring
drug
market
abund
public
rapid
public
rate
associ
virusrel
diseas
outbreak
illustr
report
indic
intens
effort
research
institut
pharmaceut
industri
address
molecular
mechan
therapeut
rout
use
treat
current
futur
coronaviru
outbreak
support
inform
avail
free
charg
http
tabl
distribut
rnai
patent
relat
sar
mer
ca
content
collect
distribut
vaccin
patent
relat
sar
mer
ca
content
collect
pdf
